Par Drugs and Chemicals Limited — Important, 07-08-2025: Updates

PAR Drugs & Chemicals' board has approved strong Q1 FY26 financial results. Revenue from operations jumped to ₹26.05 Cr, up significantly year-on-year and quarter-on-quarter. Net Profit surged to ₹3.33 Cr, with EPS at ₹2.70, reflecting robust performance. The company also renewed its banking facility of ₹1.61 Cr with Kotak Mahindra Bank. Notably, the company reported zero pending investor grievances. The trading window for insiders will open soon.